ANI Pharmaceuticals (ANIP) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ANI Pharmaceuticals (ANIP) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, losing 14.0% versus a loss of 50.9%. Over five years, ANIP leads with a +68.1% price change compared with -78.5% for RARE. Ultragenyx Pharmaceutical is the larger company by market cap ($1.68 billion vs $1.56 billion), about 1.1 times the size, while ANI Pharmaceuticals is growing revenue faster (+43.8% vs +20.2%).
On valuation, ANI Pharmaceuticals trades at a lower forward P/E (6.7x vs 11.5x for Ultragenyx Pharmaceutical). ANI Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.9% versus -85.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | RARE |
|---|---|---|
| Share price | $68.55 | $16.48 |
| Market cap | $1.56B | $1.68B |
| 1-day change | -0.84% | -4.30% |
| YTD return | -13.16% | -28.35% |
| 1-year return | -14.01% | -50.94% |
| 5-year return | +68.14% | -78.45% |
| P/E ratio (TTM) | 13.90 | — |
| Forward P/E | 6.72 | 11.50 |
| EPS (TTM) | $4.93 | $-5.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $883.37M | $673.00M |
| Revenue growth (YoY) | +43.78% | +20.18% |
| Net income (latest FY) | $78.34M | $-575.00M |
| Gross margin | 61.36% | — |
| Operating margin | 12.58% | -79.49% |
| Net margin | 8.87% | -85.44% |
| 52-week high | $87.76 | $39.89 |
| 52-week low | $67.14 | $12.73 |
| Distance from 52-week high | -21.89% | -58.69% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +50.81% | +50.49% |
| Average volume | 420.66K | 4.69M |
| Shares outstanding | 22.72M | 101.92M |
| Employees | 970 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIP has outperformed RARE by 36.9 percentage points over the past year.
- ANI Pharmaceuticals is more profitable, keeping 8.9 cents of every revenue dollar as net income versus -85.4 cents for Ultragenyx Pharmaceutical.
- ANI Pharmaceuticals grew revenue faster in its latest fiscal year (+43.78% vs +20.18%).
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
ANIP vs RARE FAQ
Which is bigger, ANI Pharmaceuticals or Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.68B compared with $1.56B for ANI Pharmaceuticals (ANIP).
Which stock has performed better over the past year, ANIP or RARE?
ANIP returned -14.01% over the past 12 months, compared with -50.94% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are ANI Pharmaceuticals and Ultragenyx Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.